Laura F. Hutchins
Researcher
Also affiliated: Roswell Park Comprehensive Cancer Center (2009–2010); City Of Hope National Medical Center (1994); Loyola University Medical Center (2004); Sunnybrook Health Science Centre (2005); Emory Healthcare (2009); Mayo Clinic (2007); Memorial Sloan Kettering Cancer Center (2003); University of Arizona (2009–2010); Johns Hopkins University (2010); University of California, Los Angeles (2008); Oregon Health & Science University (1993); The University of Texas at San Antonio Health Science Center (2005–2010); Northern Kentucky University (1993); Baylor College of Medicine (2004–2009); Georgetown University (2003); Loyola University Chicago (1996–2009); University of Michigan (1993–2004); University of Arkansas Medical Center (1988–2020); Southwest Washington Medical Center (1994); Cancer Institute (WIA) (2014); Providence Portland Medical Center (2017); Missouri Baptist Medical Center (2005–2009); University of Colorado Health (2009); Fred Hutch Cancer Center (2004); Arkansas Cardiology (2012); Central Arkansas Veterans Healthcare System (2005); Cancer Research And Biostatistics (1993–2008); Cancer Research for the Ozarks (2008); Angeles Clinic and Research Institute (2007–2009); Palmetto Hematology Oncology (2013–2014); Dana-Farber Cancer Institute (2007); Ann Arbor VA Medical Center (1993); Cancer Research Center (2010); Winthrop Rockefeller Foundation (2014–2021); University of Colorado Cancer Center (2009); Japanese Society of Medical Oncology (2009); Ann Arbor Center for Independent Living (2009); John L. McClellan Memorial Veterans Hospital (1985–1999); Synta Pharmaceuticals (United States) (2009); Arkansas Department of Agriculture (1992–2015); Memorial Hospital (1985); NSABP Foundation (2008); SWOG Cancer Research Network (1994–2008); Winship Cancer Institute (2009); Indiana University – Purdue University Indianapolis (2007); University of Missouri (2009); University of Colorado Denver (2009)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Laura F. Hutchins' research focuses on cancer treatment and patient outcomes, with a particular emphasis on breast cancer and melanoma. Her work investigates disparities in cancer care and treatment adherence, utilizing large datasets such as state cancer registries and all-payer claims databases. Recent publications include analyses of racial disparities in adherence to endocrine therapy for early-stage hormone receptor-positive breast cancer, and consistency in reporting radiation therapy data after breast-conserving surgery.
Hutchins also examines adverse events associated with cancer therapies, such as immune adverse events (irAEs) in patients receiving adjuvant ipilimumab for melanoma. Her research explores the use of immunosuppressants and their association with treatment outcomes in these cases. She has published 153 works, accumulating over 9,700 citations, and holds an h-index of 44, reflecting a significant impact in her field. She leads a research group and maintains an active lab website.
Metrics
- h-index: 44
- Publications: 153
- Citations: 9,755
Selected Publications
-
Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database (2024)
-
Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery (2023)
-
Reporting consistency in radiation therapy after breast conservative surgery between Arkansas Cancer Registry and all payers claims database. (2022)
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis (2021)
-
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition (2020)
-
Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study (2020)
-
Abstract P3-09-18: Immunization of breast cancer patients in combination with standard-of-care chemotherapy: Results of a phase Ib clinical trial (2020)
-
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 (2019)
-
In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma (2019)
-
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma. (2019)
-
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study (2019)
-
Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study (2018)
-
Liquid biopsy and its role in an advanced clinical trial for lung cancer (2018)
-
Outcomes of immunotherapy in advanced melanoma in relation to age. (2018)
-
Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component (2018)
Collaboration Network
Top Collaborators
- Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery
- Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database
- Reporting consistency in radiation therapy after breast conservative surgery between Arkansas Cancer Registry and all payers claims database.
- Consistency Between State's Cancer Registry and All-Payer Claims Database in Documented Radiation Therapy Among Patients Who Received Breast Conservative Surgery
- Racial Disparity in Adherence to Endocrine Therapy among Women with Early-Stage Hormone Receptor Positive Breast Cancer: An Analysis of Arkansas All-Payers Claims Database
- Reporting consistency in radiation therapy after breast conservative surgery between Arkansas Cancer Registry and all payers claims database.
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
- Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Similar Researchers
Based on overlapping research topics